All in all, our results confirm a significant role of YXQN against cognitive decline and Aβ aggregation in AD, through up-regulating the level of α-secretase ADAM10 in the physiological processing of APP, and down-regulating β-secretase BACE1 and γ-secretase PS1 in the pathological processing of APP. Here, ADAM10 is linked to Alzheimer disease.